tetraethylammonium has been researched along with Parkinson Disease, Secondary in 2 studies
Tetraethylammonium: A potassium-selective ion channel blocker. (From J Gen Phys 1994;104(1):173-90)
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haghdoost-Yazdi, H | 2 |
| Piri, H | 1 |
| Najafipour, R | 1 |
| Faraji, A | 2 |
| Fraidouni, N | 2 |
| Dargahi, T | 1 |
| Alipour Heidari, M | 1 |
| Movahedi, M | 1 |
| Hadibeygi, E | 1 |
| Vaezi, F | 1 |
2 other studies available for tetraethylammonium and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Blockade of fast A-type and TEA-sensitive potassium channels provide an antiparkinsonian effect in a 6-OHDA animal model.
Topics: 4-Aminopyridine; Animals; Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug | 2017 |
Significant effects of 4-aminopyridine and tetraethylammonium in the treatment of 6-hydroxydopamine-induced Parkinson's disease.
Topics: 4-Aminopyridine; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Drug Interactions; | 2011 |